In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

Key Sessions:

• Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
• Biomarkers and Cancer Vaccines
• CAR-T cell therapy, T Cell Therapy
• Tumor microenvironment
• Oncolytic Viruses
• Microbiome in Cancer Immunotherapy

To learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here